Vera Therapeutics Files Routine 8-K; No Material Changes Reported

Ticker: VERA · Form: 8-K · Filed: Jan 25, 2024 · CIK: 1831828

Vera Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyVera Therapeutics, INC. (VERA)
Form Type8-K
Filed DateJan 25, 2024
Risk Levellow
Pages5
Reading Time6 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, compliance

TL;DR

**Vera Therapeutics filed a routine 8-K, nothing major to see here.**

AI Summary

Vera Therapeutics, Inc. filed an 8-K on January 25, 2024, to report a routine corporate event under Regulation FD Disclosure and Other Events. This filing primarily serves to update the public record regarding the company's status and its Class A common stock, which is traded on The Nasdaq Stock Market LLC under the symbol VERA. For investors, this filing indicates standard compliance and no immediate material changes to the company's operations or financial health, suggesting a stable, albeit uneventful, corporate update.

Why It Matters

This filing is a standard compliance update, indicating no new significant events that would immediately impact Vera Therapeutics' stock price or business operations. It reassures investors that the company is maintaining its regulatory obligations.

Risk Assessment

Risk Level: low — This 8-K filing is purely administrative and does not disclose any new risks or material changes to the company's operations or financial condition.

Analyst Insight

A smart investor would note this as a routine compliance filing and not expect any immediate market reaction. It's a non-event that confirms the company is maintaining its regulatory obligations.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this 8-K filing by Vera Therapeutics, Inc.?

This 8-K filing by Vera Therapeutics, Inc. is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on Regulation FD Disclosure and Other Events as of January 25, 2024. It primarily serves as a routine update to the public record.

On what date was the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 25, 2024.

What is the trading symbol and exchange for Vera Therapeutics, Inc.'s common stock?

Vera Therapeutics, Inc.'s Class A common stock trades under the symbol VERA on The Nasdaq Stock Market LLC.

What is the state of incorporation for Vera Therapeutics, Inc.?

Vera Therapeutics, Inc. is incorporated in Delaware.

Does this 8-K filing indicate any significant new developments for Vera Therapeutics, Inc.?

No, this 8-K filing is a standard regulatory update under 'Regulation FD Disclosure' and 'Other Events' and does not indicate any significant new developments, material changes, or financial disclosures beyond routine corporate information.

Filing Stats: 1,445 words · 6 min read · ~5 pages · Grade level 12.1 · Accepted 2024-01-25 06:31:03

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On January 25, 2024, Vera Therapeutics, Inc. (the "Company") announced positive 72-week data from the open label extension ("OLE") period of the Company's Phase 2b ORIGIN clinical trial of atacicept in patients with immunoglobulin A nephropathy ("IgAN"). A copy of the press release is furnished as Exhibit 99.1. In connection with the data release, the Company compiled a presentation entitled "R&D Day" (the "R&D Day Presentation") that includes the week 72 data from the Phase 2b ORIGIN clinical trial referenced above. A copy of the R&D Day Presentation is furnished as Exhibit 99.2. For important information about forward-looking statements, see the slide titled "Forward-Looking Statements" in Exhibit 99.2 attached hereto. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission ("SEC") made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01

Item 8.01 Other Events. As noted in Item 7.01, on January 25, 2024, the Company announced positive 72-week data from the OLE period of the Company's Phase 2b ORIGIN clinical trial of atacicept in patients with IgAN. Atacicept is the Company's potential best-in-class, disease-modifying dual inhibitor of the cytokines B-cell activating factor and a proliferation-inducing ligand. ORIGIN is a multinational, randomized, double-blind, placebo-controlled clinical trial (n=116) evaluating the efficacy and safety of atacicept in patients with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression despite available ACE or ARB therapy. After completing the 36-week randomized, double-blind, placebo-controlled period of the Phase 2b ORIGIN trial, all participants were eligible to receive atacicept 150 mg in the OLE. Of the 116 randomized participants, 106 completed 72 weeks. Participants treated with atacicept for 72 weeks demonstrated a 62% reduction in Gd-IgA1, a reduction in the percentage of participants with hematuria to 19%, and a 48% reduction in urine protein to creatinine ratio ("UPCR") in the per-protocol ("PP") analysis. Importantly, participants had consistent and stable estimated glomerular filtration ("eGFR") with 0 mL/min/1.73m 2 change from baseline at 72 weeks. Of note, it has been shown that eGFR declines by approximately 1 mL/min/1.73m 2 per year in the general population. Atacicept 72-week data from the Phase 2b ORIGIN trial are consistent with a profile of true disease modification Participants who switched from placebo to atacicept demonstrated similar outcomes across each of the key indicators of IgAN as compared to participants originally randomized to atacicept during the first 36 weeks of the trial, including a 59% reduction in Gd-IgA1, a reduction in the percentage of participants with hematuria to 41%, and a 47% reduction in UPCR in the PP analysis. In addition, eGFR stabilization was observed in p

Forward-looking Statements

Forward-looking Statements

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Vera Therapeutics, Inc., dated January 25, 2024. 99.2 Slide presentation entitled "R&D Day". 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vera Therapeutics, Inc. Dated: January 25, 2024 By: /s/ Marshall Fordyce, M.D. Marshall Fordyce, M.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing